A subgroup evaluation of the section 3 TiNivo-2 trial alluded to the potential, but comparable, advantage of Fotivda (tivozanib) alone or together with Opdivo (nivolumab) in sufferers with metastatic renal cell carcinoma (RCC) who had progressed on first-line immune checkpoint inhibitor (ICI)-based regimens.
In line with Dr. Alexander Chehrazi-Raffle, the Fotivda monotherapy demonstrated comparable or superior progression-free survival and goal response charges versus the mixture remedy in each cohorts. The median progression-free survival was 9.2 months with Fotivda and 9.3 months with Fotivda plus Opdivo. Furthermore, the general response charges have been 32.4% and 24.2%, respectively. Within the TKI/ICI cohort, progression-free survival and general response fee have been longer and better with Fotivda monotherapy.
To additional broaden on the subject, Chehrazi-Raffle sat down for an interview with CURE, dwell from the 2025 ASCO Annual Assembly, the place he mentioned how this examine could assist make clear whether or not Fotivda alone or mixed with Opdivo is a greater second-line therapy possibility for sufferers whose mRCC has progressed after preliminary immunotherapy. Moreover, he touched on if the effectiveness of second-line Fotivda remedy could range relying on the particular therapies sufferers beforehand acquired.
Chehrazi-Raffle is an assistant professor within the Division of Medical Oncology & Therapeutics Analysis, at Metropolis of Hope, situated in Duarte, California.
Transcript:
Yeah, I believe the subgroup evaluation reiterates what we discovered within the section 3 trial: the mixture of immunotherapy plus VEGF will not be superior to VEGF alone after sufferers have already progressed on an immunotherapy routine. What it did elucidate, although, is that Fotivda might be thought-about as monotherapy on the 1.34 milligram dose within the second-line setting.
We noticed extra immune-related toxicity, not surprisingly, within the sufferers who acquired Opdivo. However so far as whether or not or not the anticipated negative effects associated to VEGF TKIs have been greater within the Fotivda monotherapy arm versus the mixture arm, the reply can be not likely noticeably.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.
